Article ID Journal Published Year Pages File Type
3992160 Journal of Thoracic Oncology 2007 5 Pages PDF
Abstract
Pemetrexed with bortezomib is feasible and tolerable at recommended single-agent doses. Based on the observed efficacy, a phase II study in non-small cell lung cancer is warranted.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer
Authors
, , , , , , , , , ,